Efficacy and Safety of Transdermal Buprenorphine: A Randomized, Placebo-Controlled Trial in 289 Patients with Severe Cancer Pain Philippe Poulain, MD, Willy Denier, MD, Joep Douma, MD, Klaus Hoerauf, MD, PhD, Mirko Šamija, MD, Maciej Sopata, MD, Gernot Wolfram, MD Journal of Pain and Symptom Management Volume 36, Issue 2, Pages 117-125 (August 2008) DOI: 10.1016/j.jpainsymman.2007.09.011 Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 1 Patient flow chart. aMultiple reasons for discontinuation of study could be mentioned. Journal of Pain and Symptom Management 2008 36, 117-125DOI: (10.1016/j.jpainsymman.2007.09.011) Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 2 Mean daily pain intensity (a) and mean intake of rescue medication (b) during the run-in phase and maintenance phase. NRS pain scores and consumption of rescue medication are given as mean+95% confidence intervals. Journal of Pain and Symptom Management 2008 36, 117-125DOI: (10.1016/j.jpainsymman.2007.09.011) Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions